Celcuity Inc. (CELC)

Celcuity Inc. is trading at $60.81, up 1.52% on the session. The 50 day average sits at $84.27 and the 200 day at $103.07, which puts the stock in a downtrend. RSI is at 23.7, which reads as oversold, and MACD is bearish crossover. Volume is volume spike.

The nearest support is around $58.98 with resistance near $87.50, so that band frames the current range. Average daily movement is roughly $4.52, or about 7.4% of the share price, which is what any stop placement has to allow for. The overall health score of 24 out of 100 combines a trend score of 0, momentum of 34 and a risk score of 48.

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.